Ocular Therapeutix
OCUL
7.23
-0.11
-1.50%
Ocular Therapeutix
US · OCUL
#2978 by market cap
Listed 1970
7.23
-0.11
-1.50%
Live - 5344 symbols - heartbeat 413s ago
· 2026-10-08 07:07
Pre-market
7.25
+0.28%
After-hours
7.25
+0.28%
Overnight
7.18
-0.69%
- Market cap
- 1.59B
- P/E (TTM)i
- -5.16
- P/Bi
- 3.05
- EPSi
- -1.42
- Div yieldi
- 0.00%
- 52W posi
- 10%
Reader sentiment
Are you bullish or bearish on OCUL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.24, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -18.47% YoY
Margins
- Gross margin
- 87.35%
- Operating margin
- -519.75%
- Net margin
- -511.90%
Key ratios & quality
- Enterprise valuei
- 924.92M
- Altman Z-Scorei
- 4.24
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.99M | 4.23M | 17.40M | 43.52M | 51.49M | 58.44M | 63.72M | 51.95M |
| Gross profit | 1.53M | 1.90M | 15.32M | 39.12M | 46.95M | 53.16M | 58.10M | 45.38M |
| Selling & admin expenses | 23.73M | 46.61M | 49.47M | 67.07M | 72.15M | 74.49M | 102.24M | 118.30M |
| Research & development | 36.92M | 41.09M | 28.69M | 50.08M | 53.46M | 61.06M | 127.64M | 197.10M |
| Operating profit | -59.12M | -85.80M | -62.85M | -78.04M | -78.65M | -82.38M | -171.78M | -270.02M |
| Pretax profit | -59.98M | -86.37M | -155.64M | -6.55M | -71.04M | -80.74M | -193.51M | -265.94M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -59.98M | -86.37M | -155.64M | -6.55M | -71.04M | -80.74M | -193.51M | -265.94M |
| Basic EPS | -2 | -2 | -3 | 0 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.57 | -1.91 | -2.56 | -0.98 | -0.97 | -1.02 | -1.22 | -1.42 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 10.70M | 13.46M | 14.54M | 13.25M | 10.79M | 13.48M |
| Gross profit | 9.44M | 11.52M | 12.77M | 11.66M | 9.46M | 11.46M |
| Selling & admin expenses | 30.50M | 28.08M | 29.11M | 30.62M | 36.58M | 39.44M |
| Research & development | 42.86M | 51.08M | 52.36M | 50.80M | 66.21M | 54.14M |
| Operating profit | -63.92M | -67.64M | -68.70M | -69.76M | -93.34M | -82.11M |
| Pretax profit | -64.05M | -67.81M | -69.42M | -64.65M | -88.61M | -78.76M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -64.05M | -67.81M | -69.42M | -64.65M | -88.61M | -78.76M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.38 | -0.39 | -0.38 | -0.29 | -0.40 | -0.35 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 56.19M | 60.17M | 246.16M | 191.30M | 129.63M | 232.24M | 440.99M | 782.13M |
| Cash & ST investments | 54.06M | 54.44M | 228.06M | 164.16M | 102.30M | 195.81M | 392.10M | 737.06M |
| Inventory | 217.00K | 954.00K | 1.20M | 1.25M | 1.97M | 2.31M | 3.04M | 3.56M |
| Total assets | 73.04M | 78.74M | 261.86M | 204.89M | 149.29M | 252.06M | 457.94M | 808.06M |
| Total current liabilities | 9.16M | 12.03M | 26.66M | 26.34M | 31.40M | 34.90M | 41.35M | 50.81M |
| Short-term debt | -- | 1.13M | 9.65M | 1.62M | 1.60M | 1.59M | 1.93M | 2.82M |
| Long-term debt | 24.79M | 49.31M | 41.24M | 51.44M | 54.01M | 74.93M | 68.51M | 71.34M |
| Total liabilities | 37,168,000.00 | 82,370,000.00 | 185,768,000.00 | 116,888,000.00 | 113,910,000.00 | 160,929,000.00 | 142,591,000.00 | 153,747,000.00 |
| Total equity | 35.88M | -3.63M | 76.10M | 88.00M | 35.38M | 91.13M | 315.34M | 654.31M |
| Retained earnings | -297.24M | -383.62M | -539.25M | -545.80M | -616.84M | -697.58M | -891.08M | -1.16B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 387.69M | 433.38M | 386.98M | 782.13M | 706.00M | 644.43M |
| Cash & ST investments | 349.68M | 391.13M | 344.77M | 737.06M | 666.70M | 598.64M |
| Inventory | 3.27M | 3.04M | 3.49M | 3.56M | 3.74M | 3.83M |
| Total assets | 405.92M | 451.33M | 410.88M | 808.06M | 732.53M | 671.32M |
| Total current liabilities | 37.93M | 42.93M | 49.29M | 50.81M | 47.68M | 49.17M |
| Short-term debt | 2.16M | 2.63M | 2.76M | 2.82M | 3.17M | 3.12M |
| Long-term debt | 69.20M | 69.91M | 70.62M | 71.34M | 72.06M | 72.80M |
| Total liabilities | 139,990,000.00 | 145,417,000.00 | 152,653,000.00 | 153,747,000.00 | 150,955,000.00 | 151,276,000.00 |
| Total equity | 265.93M | 305.92M | 258.23M | 654.31M | 581.57M | 520.04M |
| Retained earnings | -955.14M | -1.02B | -1.09B | -1.16B | -1.25B | -1.32B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -49.23M | -77.58M | -53.55M | -65.55M | -59.60M | -70.23M | -134.68M | -204.88M |
| Depreciation & amortization | 2.29M | 2.53M | 2.77M | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| Free cash flow | -51.12M | -79.82M | -54.40M | -66.74M | -63.32M | -76.32M | -135.97M | -216.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 61.87M | 37.99M | 225.43M | 985.00K | 940.00K | 118.11M | 317.37M | 541.18M |
| Ending cash balance | 60.68M | 56.20M | 229.82M | 165.93M | 104.06M | 197.57M | 393.72M | 738.67M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -44.67M | -55.24M | -50.73M | -54.25M | -65.99M | -67.27M |
| Depreciation & amortization | 981.00K | 1.03M | 1.07M | 1.25M | 1.28M | 1.85M |
| Free cash flow | -46.60M | -56.48M | -56.72M | -57.09M | -70.66M | -70.64M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 446.44M | -- | -- |
| Ending cash balance | 351.30M | 392.75M | 346.39M | 738.67M | 668.31M | 600.26M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -193.41 | -535.72 | -429.55 | -7.99 | -115.16 | -127.64 | -95.21 | -54.85 |
| ROA %i | -93.37 | -113.81 | -91.39 | -2.81 | -40.11 | -40.23 | -54.51 | -42.01 |
| ROIC %i | -119.09 | -138.72 | -156.68 | 0.06 | -52.56 | -53.53 | -70.79 | -48.55 |
| 5-year avg ROE %i | -- | -201.62 | -276.81 | -265.77 | -256.36 | -243.21 | -155.11 | -80.17 |
| EBIT margin %i | -2,926.58 | -1,899.01 | -855.42 | 0.27 | -124.32 | -118.74 | -282.36 | -489.12 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.14 | 5.00 | 9.23 | 7.26 | 4.13 | 6.66 | 10.66 | 15.39 |
| Quick ratioi | 5.92 | 4.74 | 9.01 | 7.04 | 3.94 | 6.36 | 10.26 | 15.11 |
| Debt / assetsi | 33.94 | 75.37 | 22.32 | 28.79 | 43.06 | 33.08 | 16.55 | 9.53 |
| LT debt / equityi | 69.10 | -- | 64.12 | 65.18 | 177.18 | 89.76 | 23.42 | 11.33 |
| Interest coveragei | -33.49 | -13.16 | -22.00 | 0.02 | -9.12 | -6.12 | -13.25 | -21.47 |
| Revenue CAGR (3Y) %i | 4.38 | 30.84 | 108.39 | 179.65 | 130.10 | 49.75 | 13.55 | 0.30 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -57.19 | -63.41 | -81.83 | -54.85 | -68.55 | -72.99 |
| ROA %i | -40.79 | -44.76 | -55.41 | -42.01 | -51.03 | -53.70 |
| ROIC %i | -48.61 | -53.15 | -66.44 | -48.55 | -59.70 | -63.65 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -302.11 | -360.75 | -425.87 | -489.12 | -535.90 | -557.19 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 10.22 | 10.09 | 7.85 | 15.39 | 14.81 | 13.11 |
| Quick ratioi | 9.89 | 9.82 | 7.62 | 15.11 | 14.49 | 12.79 |
| Debt / assetsi | 18.78 | 17.05 | 18.74 | 9.53 | 10.85 | 11.83 |
| LT debt / equityi | 27.85 | 24.29 | 28.75 | 11.33 | 13.12 | 14.66 |
| Interest coveragei | -14.40 | -16.58 | -19.62 | -21.47 | -23.98 | -25.43 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing and commercializing innovative therapies for retinal diseases and other eye conditions100.00%
Quote time 2026-10-08 07:07:20 · For reference only, not investment advice and not tailored to your situation.